You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 47 No. 12, December 1990 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Effects of Physostigmine on Spatial Attention in Patients With Progressive Supranuclear Palsy

Caroline Kertzman, PhD; David Lee Robinson, PhD; Irene Litvan, MD

Arch Neurol. 1990;47(12):1346-1350.


Abstract

• We tested patients with progressive supranuclear palsy and control subjects on a task of visuospatial attention. Targets preceded by cues on the same side were termed validly cued; and those on the opposite side, invalidly cued. For all subjects, validly cued targets were responded to faster than those that were invalidly cued. The difference between reaction times for invalidly and validly cued targets, which is hypothesized to measure attentional movement, was significantly increased for the patients. The performance of the controls on certain neuropsychological tests was correlated with their attentional ability. These correlations were altered by progressive supranuclear palsy. Physostigmine treatment of the patients induced a speeding of responses to invalidly cued targets as a function of the duration of the disease. These studies show defects in cognition and attention in patients with progressive supranuclear palsy and demonstrate that physostigmine reduces some of the abnormal visual attentional performance.



Author Affiliations

From the Section on Visual Behavior, Laboratory of Sensorimotor Research, National Eye Institute (Drs Kertzman and Robinson), and the Experimental Therapeutics Branch, National Institute of Neurological Disorders and Stroke (Dr Litvan), National Institutes of Health, Bethesda, Md.


Footnotes

Accepted for publication June 15, 1990.

Reprint requests to Section on Visual Behavior, Laboratory of Sensorimotor Research, National Institutes of Health, Bldg 10, Room 10C101, Bethesda, MD 20892 (Dr Robinson).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cholinergic systems in progressive supranuclear palsy
Warren et al.
Brain 2005;128:239-249.
ABSTRACT | FULL TEXT  

Pharmacological Therapy in Progressive Supranuclear Palsy
Kompoliti et al.
Arch Neurol 1998;55:1099-1102.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1990 American Medical Association. All Rights Reserved.